JPWO2022180271A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022180271A5 JPWO2022180271A5 JP2023551762A JP2023551762A JPWO2022180271A5 JP WO2022180271 A5 JPWO2022180271 A5 JP WO2022180271A5 JP 2023551762 A JP2023551762 A JP 2023551762A JP 2023551762 A JP2023551762 A JP 2023551762A JP WO2022180271 A5 JPWO2022180271 A5 JP WO2022180271A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- set forth
- sequence set
- multispecific antibody
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000427 antigen Substances 0.000 claims 15
- 102000036639 antigens Human genes 0.000 claims 15
- 108091007433 antigens Proteins 0.000 claims 15
- 229920001184 polypeptide Polymers 0.000 claims 11
- 108090000765 processed proteins & peptides Proteins 0.000 claims 11
- 102000004196 processed proteins & peptides Human genes 0.000 claims 11
- 108010003723 Single-Domain Antibodies Proteins 0.000 claims 7
- 101100112922 Candida albicans CDR3 gene Proteins 0.000 claims 5
- 102100035361 Cerebellar degeneration-related protein 2 Human genes 0.000 claims 5
- 101000737796 Homo sapiens Cerebellar degeneration-related protein 2 Proteins 0.000 claims 5
- 101000998120 Homo sapiens Interleukin-3 receptor subunit alpha Proteins 0.000 claims 5
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 claims 4
- 101000737793 Homo sapiens Cerebellar degeneration-related antigen 1 Proteins 0.000 claims 4
- 235000001014 amino acid Nutrition 0.000 claims 4
- 210000004027 cell Anatomy 0.000 claims 4
- 102000052088 human IL3RA Human genes 0.000 claims 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 238000006467 substitution reaction Methods 0.000 claims 3
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 210000001744 T-lymphocyte Anatomy 0.000 claims 2
- 230000015572 biosynthetic process Effects 0.000 claims 2
- 239000000833 heterodimer Substances 0.000 claims 2
- 230000035772 mutation Effects 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 208000025324 B-cell acute lymphoblastic leukemia Diseases 0.000 claims 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 1
- 208000017604 Hodgkin disease Diseases 0.000 claims 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 1
- 208000030289 Lymphoproliferative disease Diseases 0.000 claims 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 1
- 108091008874 T cell receptors Proteins 0.000 claims 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims 1
- 230000003213 activating effect Effects 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 210000003719 b-lymphocyte Anatomy 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 208000035269 cancer or benign tumor Diseases 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims 1
- 201000009277 hairy cell leukemia Diseases 0.000 claims 1
- 239000000710 homodimer Substances 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21159698.6 | 2021-02-26 | ||
| EP21159698 | 2021-02-26 | ||
| US202163166339P | 2021-03-26 | 2021-03-26 | |
| US63/166,339 | 2021-03-26 | ||
| US202163274709P | 2021-11-02 | 2021-11-02 | |
| US63/274,709 | 2021-11-02 | ||
| EP21211114.0 | 2021-11-29 | ||
| EP21211114 | 2021-11-29 | ||
| PCT/EP2022/054993 WO2022180271A1 (en) | 2021-02-26 | 2022-02-28 | Antibodies that bind CD123 and gamma-delta T cell receptors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024507937A JP2024507937A (ja) | 2024-02-21 |
| JPWO2022180271A5 true JPWO2022180271A5 (https=) | 2025-02-27 |
| JP2024507937A5 JP2024507937A5 (https=) | 2025-02-27 |
Family
ID=80786427
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023551762A Pending JP2024507937A (ja) | 2021-02-26 | 2022-02-28 | Ｃｄ１２３及びガンマデルタｔ細胞受容体に結合する抗体 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20240141071A1 (https=) |
| EP (1) | EP4298125A1 (https=) |
| JP (1) | JP2024507937A (https=) |
| KR (1) | KR20230169950A (https=) |
| AU (1) | AU2022225091A1 (https=) |
| BR (1) | BR112023017099A2 (https=) |
| CA (1) | CA3209454A1 (https=) |
| MX (1) | MX2023009950A (https=) |
| WO (1) | WO2022180271A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4292610A1 (en) * | 2022-06-15 | 2023-12-20 | LAVA Therapeutics N.V. | Variant antibodies that bind gamma-delta t cell receptors |
| WO2025012118A2 (en) * | 2023-07-07 | 2025-01-16 | LAVA Therapeutics N.V. | 5t4 binding agents and methods of use |
| CN118496370A (zh) * | 2024-06-07 | 2024-08-16 | 南方医科大学深圳医院 | 一种靶向alox5纳米抗体及其应用 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US20100081792A1 (en) | 2001-06-28 | 2010-04-01 | Smithkline Beecham Corporation | Ligand |
| FR2879605B1 (fr) | 2004-12-16 | 2008-10-17 | Centre Nat Rech Scient Cnrse | Production de formats d'anticorps et applications immunologiques de ces formats |
| US10155816B2 (en) | 2005-11-28 | 2018-12-18 | Genmab A/S | Recombinant monovalent antibodies and methods for production thereof |
| US8227577B2 (en) | 2007-12-21 | 2012-07-24 | Hoffman-La Roche Inc. | Bivalent, bispecific antibodies |
| CN102282168A (zh) | 2008-11-18 | 2011-12-14 | 梅里麦克制药股份有限公司 | 人血清白蛋白接头以及其结合物 |
| WO2010111625A1 (en) | 2009-03-27 | 2010-09-30 | Zymogenetics, Inc. | Compositions and methods for using multispecific-binding proteins comprising an antibody-receptor combination |
| KR101224468B1 (ko) | 2009-05-20 | 2013-01-23 | 주식회사 파멥신 | 신규한 형태의 이중표적항체 및 그 용도 |
| PL2606064T3 (pl) | 2010-08-16 | 2015-07-31 | Novimmune Sa | Sposoby wytwarzania wieloswoistych i wielowartościowych przeciwciał |
| SI2838917T1 (sl) | 2012-04-20 | 2019-11-29 | Merus Nv | Postopki in sredstva za produkcijo heterodimernih IG-podobnih molekul |
| DK2924052T3 (da) | 2012-11-21 | 2019-09-30 | Pharmabcine Inc | Dual-target-antistof målrettet mod vegfr-2 og dll4, og farmaceutisk sammensætning omfattende samme |
| EP3129404B1 (en) * | 2014-04-10 | 2026-01-28 | LAVA Therapeutics N.V. | Immunoglobulins binding human vgamma9vdelta2 t cell receptors |
| BR112020020604A2 (pt) * | 2018-04-11 | 2021-01-12 | Inhibrx, Inc. | Construções de polipeptídeo multiespecífico tendo ligação restrita de cd3 e métodos e usos relacionados |
| WO2020060406A1 (en) * | 2018-09-19 | 2020-03-26 | Lava Therapeutics B.V. | Novel bispecific antibodies for use in the treatment of hematological malignancies |
| JP2022532868A (ja) * | 2019-05-04 | 2022-07-20 | インヒブルクス インコーポレイテッド | Ｃｄ１２３結合性ポリペプチド及びその使用 |
| EP3965818A4 (en) | 2019-05-08 | 2023-05-31 | Janssen Biotech, Inc. | MATERIALS AND METHODS FOR MODULATION OF T-CELL-MEDIATED IMMUNITY |
-
2022
- 2022-02-28 MX MX2023009950A patent/MX2023009950A/es unknown
- 2022-02-28 WO PCT/EP2022/054993 patent/WO2022180271A1/en not_active Ceased
- 2022-02-28 CA CA3209454A patent/CA3209454A1/en active Pending
- 2022-02-28 JP JP2023551762A patent/JP2024507937A/ja active Pending
- 2022-02-28 US US18/278,956 patent/US20240141071A1/en active Pending
- 2022-02-28 KR KR1020237032819A patent/KR20230169950A/ko active Pending
- 2022-02-28 EP EP22708159.3A patent/EP4298125A1/en active Pending
- 2022-02-28 AU AU2022225091A patent/AU2022225091A1/en active Pending
- 2022-02-28 BR BR112023017099A patent/BR112023017099A2/pt unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9688773B2 (en) | C-Met antibody combinations | |
| JP7503642B2 (ja) | 微小ガイダンス及びナビゲーションコントロール（ｍｉｎｉＧＮＣ）抗体様タンパク質、その製造方法及び使用方法 | |
| JP2021522162A5 (https=) | ||
| JP2020502233A5 (https=) | ||
| CA3125120A1 (en) | Antibody fusion protein, preparation method therefor and application thereof | |
| IL267589B2 (en) | Adam9-binding molecules, and methods of use thereof | |
| JP2024156878A5 (https=) | ||
| JPWO2020159368A5 (https=) | ||
| CN113574069A (zh) | 抗pd-l1抗体及其用途 | |
| JPWO2022102768A5 (https=) | ||
| JPWO2021222578A5 (https=) | ||
| JPWO2022180271A5 (https=) | ||
| Spasevska et al. | Advances in bispecific antibodies engineering: Novel concepts for immunotherapies | |
| JPWO2022122973A5 (https=) | ||
| JPWO2022008646A5 (https=) | ||
| KR20180010178A (ko) | Jag1에 결합하는 항체 치료제 | |
| JPWO2023098888A5 (https=) | ||
| JPWO2020218951A5 (https=) | ||
| JP7854121B2 (ja) | 微小ガイダンス及びナビゲーションコントロール（ｍｉｎｉＧＮＣ）抗体様タンパク質、その製造方法及び使用方法 | |
| US20260015430A1 (en) | Antigen binding protein specific for transmembrane activator and caml interactor (taci) | |
| WO2025045018A1 (en) | Anti-gamma delta tcr antibodies and uses thereof | |
| US20250376524A1 (en) | Tetravalent multispecific binding molecules and methods of use thereof | |
| WO2019072274A1 (zh) | 一种激动型4-1bb单克隆抗体 | |
| RU2024136797A (ru) | Вариантные антитела, которые связывают гамма-дельта-т-клеточные рецепторы | |
| WO2025226693A1 (en) | Sirp gamma antibodies for treatment of epstein–barr virus infections |